Lichturtikaria – Urticaria solaris

Goetze, Steven; Elsner, Peter

doi:10.1111/ddg.100_12809

Cited by 4 publications

(5 citation statements)

References 23 publications

(56 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Solar urticaria is a rare form of physical urticaria and its pathophysiology is still largely unknown, despite the likely significant role played by the mast cells activated by immunoglobulins E [1,2].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Solar urticaria, a disease with many dark sides: is omalizumab the right therapeutic response? Reflections from a clinical case report

2019

View full text Add to dashboard Cite

AbstractSolar urticaria is a rare type of photodermatosis that significantly reduces the quality of life of the subjects affected, with a risk of anaphylaxis should the entire body be exposed to the sun. Patients are forced to modify and limit their normal activities, and since the symptoms are triggered by exposure to sun, which is difficult if not impossible to avoid in everyday life, a safe and effective therapy appears to be essential.Unfortunately, traditional therapies in a discrete number of patients are unable to provide adequate and safe answers.We describe the case of an 18-year-old woman who began to manifest the first symptoms walking under the spring sunshine. A few minutes after sun exposure, itching and burning sensation began, followed immediately by erythema appearance in the photoexposed skin areas.She was treated with non-sedating H1-blocking antihistamines and leukotriene antagonist with no success, so we decided to treat with omalizumab.The satisfactory response after the failure of previous standard therapeutic strategies, confirms the effectiveness of this molecule in the treatment of solar urticaria, which despite what reported in several studies, has not yet been recognized and authorized by the competent Health Authorities in the treatment of this condition.

show abstract

Section: Discussionmentioning

confidence: 99%

“…It can occur throughout an individuals life span but the mean age of onset is in the fourth decade. We do not have a precise data of prevalence and incidence, but literature reported figures range from 2.3% to 17.8% [1].…”

Section: Introductionmentioning

confidence: 99%

Solar urticaria, a disease with many dark sides: is omalizumab the right therapeutic response? Reflections from a clinical case report

2019

View full text Add to dashboard Cite

show abstract

“…A reaction between a precursor factor in the skin and an action spectrum is assumed in literature [1]. The resulting photo allergen induces immunoglobulin E production triggering mast cell degranulation, an erythematous flare reaction and wheals or itch appear as a result of type I allergy [3,4]. During the diagnostic process, we were surprised by the coincidence of the use of gel manicure systems and UV nail lamps and the development of solar urticaria.…”

Section: Discussionmentioning

confidence: 99%

Solar urticaria related to ultraviolet nail lamps: a case report

Coninx¹,

Aerts²,

Bervoets³

2019

Our Dermatol Online

View full text Add to dashboard Cite

Solar urticaria is a rare chronic skin condition triggered via (an) uncharacterized chromophore(s) and characterized by skin lesions and/or itch immediately after sun exposure. We present a 50-year-old woman who presented to us with a history of an itchy and burning sensation after a few minutes of sun exposure, first noticed after applying gel nails for the first time. We suggest that a photoallergen can be formed during the polymerization and hardening process of gel nails.

show abstract

“…Because of its rarity, there are few data on the prevalence and incidence. SU usually manifests itself in the fourth decade of life and it occurs more commonly in women than men, regardless skin phototype and ethnicity [ 1 ]. First line treatment is based on second-generation H 1 -antihistamines, which can be increased up 2–4 fold the standard dosage to achieve clinical remission.…”

Section: Introductionmentioning

confidence: 99%

Long term treatment with omalizumab in adolescent with refractory solar urticaria

et al. 2021

View full text Add to dashboard Cite

Background Solar urticaria represents an uncomfortable form of chronic inducible urticaria. First and second-line treatments are ineffective in some patients, leading to an impairment in their quality of life. Omalizumab represents a safe therapeutic option in case of refractory solar urticaria. Case presentation We update a case of a 21-year-old Caucasian girl affected by solar urticaria from the age of 14. Poor disease control was achieved with standard or high-dose of H1-antihistamines. Several omalizumab courses, including a 1-year-long course, were practiced resulting in clinical remission and significant improvement in patient’s quality of life. Conclusion Our experience confirms the effectiveness and safety of omalizumab for the management of refractory solar urticaria. Future studies are awaited in order to monitor long term effects and chronic doses of this treatment, particularly in patients who need concomitant therapy with antihistamines.

show abstract

Lichturtikaria – Urticaria solaris

Cited by 4 publications

References 23 publications

Solar urticaria, a disease with many dark sides: is omalizumab the right therapeutic response? Reflections from a clinical case report

Solar urticaria, a disease with many dark sides: is omalizumab the right therapeutic response? Reflections from a clinical case report

Solar urticaria related to ultraviolet nail lamps: a case report

Long term treatment with omalizumab in adolescent with refractory solar urticaria

Contact Info

Product

Resources

About